NATCO Pharma limited ties-up with Akorn Inc

Hyderabad, Apr 23: NATCO Pharma limited has tied-up with USA based Akorn Inc for API supply and margin sharing to commercialize two ANDA injectable drug products.

The two ANDA drug products would focus on the anti-emetic and cancer related markets and have a combined current market size of approximatley $ 875 millon, according to a press release.

NATCO would be responsible for the supply of active pharmaceutical ingredients for both drug products, while Akorn would be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospitals and health care markets in USA and Canada.

Akron's President and Chief Executive Officer Arthur S Przbyl said 'NATCO has agreed to supply API for both products in exchange for a gross margin sharing business relationship.

NATCO Pharma Chairman Chowdary V Nannapani said the agreement helps in bringing down development expense and compete with vertically integrated firms in a competitive generic business, a press release said here today.

UNI